Profil
Robert Scott McDowell occupe le poste de directeur scientifique de MyoKardia, Inc. Il était auparavant vice-président de la recherche chez Sagimet Biosciences, Inc, scientifique principal chez Genentech, Inc, vice-président de la recherche chez Sunesis Pharmaceuticals, Inc et directeur de la chimie structurelle chez Axys Pharmaceuticals, Inc. Il a obtenu un diplôme de premier cycle à l'université Butler et un doctorat à l'université de Californie, Berkeley.
Anciens postes connus de Robert McDowell
Sociétés | Poste | Fin |
---|---|---|
MYOKARDIA, INC. | Directeur Technique/Scientifique/R&D | 01/11/2020 |
SAGIMET BIOSCIENCES INC. | Directeur Technique/Scientifique/R&D | 01/07/2012 |
VIRACTA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 04/08/2008 |
Axys Pharmaceuticals, Inc.
Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/2000 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Directeur Technique/Scientifique/R&D | 01/01/1999 |
Formation de Robert McDowell
Butler University | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
SAGIMET BIOSCIENCES INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Axys Pharmaceuticals, Inc.
Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |